BioSpace News Archive

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2023 before the market opens on April 25, 2023, and will hold a conference call to discuss the results at 9:00 a.m. Eastern Time.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the Phase 1 Trial of its breast cancer vaccine.

AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T therapy at the annual 2023 AACR conference.

Nurix Therapeutics, Inc. today announced presentations covering its targeted protein degradation programs, including the structural disclosure of NX-2127 and new preclinical data for NX-2127 and NX-5948, highlighting their superior activity against acquired mutations in Bruton’s tyrosine kinase (BTK), a key therapeutic target in the treatment of B-cell malignancies.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced positive monotherapy dose escalation data for its investigational, highly selective and potent pan-RAF inhibitor, exarafenib, from Part A1 of its ongoing global Phase 1 KN-8701 clinical trial.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate) today announced the addition of two new internally developed next generation development candidates to its targeted oncology pipeline – a brain penetrant mitogen-activated protein kinase (MEK) inhibitor and a highly selective mesenchymal-epithelial transition factor gene (c-MET) inhibitor.

BeiGene, Ltd., and SpringWorks Therapeutics, Inc., announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in combination with SpringWorks’ MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors with RAS mutations, RAF mutations and other MAPK pathway aberrations.

Waters Corporation (NYSE:WAT) will hold its Q1 2023 financial results conference call live on Tuesday, May 9th 2023 at 8:00 a.m. Eastern Time.

Dyve Biosciences, Inc. (“Dyve”) today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17-20, 2023.